Wall Street brokerages predict that Syros Pharmaceuticals Inc (NASDAQ:SYRS) will announce ($0.41) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Syros Pharmaceuticals’ earnings, with estimates ranging from ($0.45) to ($0.39). Syros Pharmaceuticals posted earnings of ($0.43) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 4.7%. The business is expected to announce its next quarterly earnings results on Tuesday, August 6th.
According to Zacks, analysts expect that Syros Pharmaceuticals will report full year earnings of ($1.79) per share for the current year, with EPS estimates ranging from ($1.99) to ($1.67). For the next year, analysts expect that the firm will report earnings of ($1.82) per share, with EPS estimates ranging from ($2.19) to ($1.59). Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Syros Pharmaceuticals.
Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings results on Wednesday, May 1st. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.57) by $0.08. Syros Pharmaceuticals had a negative net margin of 3,012.04% and a negative return on equity of 74.28%. The company had revenue of $0.45 million during the quarter, compared to the consensus estimate of $0.42 million.
In other Syros Pharmaceuticals news, major shareholder Venture Fund Vii L.P. Arch sold 63,000 shares of the company’s stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $7.77, for a total value of $489,510.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 14.80% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently modified their holdings of the stock. Northern Trust Corp boosted its holdings in Syros Pharmaceuticals by 0.7% in the fourth quarter. Northern Trust Corp now owns 306,167 shares of the company’s stock worth $1,705,000 after purchasing an additional 2,179 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. boosted its holdings in Syros Pharmaceuticals by 8.3% in the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 40,380 shares of the company’s stock worth $369,000 after purchasing an additional 3,100 shares during the last quarter. Alps Advisors Inc. boosted its holdings in Syros Pharmaceuticals by 4.5% in the first quarter. Alps Advisors Inc. now owns 81,287 shares of the company’s stock worth $743,000 after purchasing an additional 3,519 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Syros Pharmaceuticals by 3.3% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 122,561 shares of the company’s stock worth $683,000 after purchasing an additional 3,900 shares during the last quarter. Finally, BNP Paribas Arbitrage SA purchased a new stake in Syros Pharmaceuticals in the first quarter worth approximately $48,000. Institutional investors own 56.16% of the company’s stock.
SYRS stock traded up $0.12 during trading on Wednesday, reaching $7.52. The company had a trading volume of 1,710 shares, compared to its average volume of 305,879. Syros Pharmaceuticals has a 52 week low of $5.17 and a 52 week high of $13.16. The stock has a market cap of $313.98 million, a P/E ratio of -3.94 and a beta of 1.94. The business’s 50 day moving average price is $7.18. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.19 and a current ratio of 5.19.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.
Read More: How to Use a Moving Average for Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.